Table 3.

Correlation between the baseline and clinical information for research participants with psoriasis, miR-203, and its target genes.

		Age	BMI	FH	Onset	Duration	Treatment	PASI	Severity
MiR203	r (PCorr)	0.056	−0.105	−0.026	−0.081	−0.056	−0.024	0.042	0.062
	PAss value	0.390	0.106	0.775	0.382	0.541	0.797	0.647	0.504
TNF-α	r (PCorr)	−0.157*	0.127*	0.149	−0.082	−0.032	0.098	−0.101	−0.061
	PAss value	0.015	0.050	0.104	0.373	0.729	0.289	0.274	0.509
SOCS3	r (PCorr)	−0.118	0.132*	0.230*	−0.016	0.057	0.104	−0.103	0.010
	PAss value	0.068	0.042	0.012	0.860	0.533	0.258	0.263	0.910
SOCS6	r (PCorr)	−0.101	0.151*	0.108	−0.006	0.087	0.054	−0.043	−0.031
	PAss value	0.118	0.019	0.241	0.948	0.344	0.558	0.645	0.738
TP63	r (PCorr)	−0.105	0.166**	0.090	0.024	−0.033	0.165	−0.025	0.031
	PAss value	0.106	0.010	0.330	0.794	0.718	0.072	0.790	0.737
IL-8	r (PCorr)	−0.151*	0.163*	0.054	−0.105	0.026	0.026	0.000	0.013
	PAss value	0.019	0.011	0.557	0.252	0.779	0.781	0.999	0.888
IL-24	r (PCorr)	−0.124	0.140*	0.082	−0.030	−0.030	0.052	−0.070	−0.030
	PAss value	0.054	0.030	0.375	0.747	0.746	0.575	0.448	0.743

^*Correlation is significant at the 0.05 level (2-tailed). ^**Correlation is significant at the 0.01 level (2-tailed). Spearman's correlation analysis is expressed as a correlation coefficient (r) and p-values (P_Corr). BMI, Body Mass Index; FH, Family History; Onset; The age of disease onset; PASI, Psoriasis Area and Severity Index.